SK-1

Enzo Announces Issuance of U.S. Patent for Methods of Using Proprietary Compound SK1-I in Patients; Exploring Options for Development as a Potential Treatment for COVID-19

Retrieved on: 
Wednesday, April 29, 2020
Organic compounds, Lipids, Sphingosine kinase 1, Biomolecules, Chemistry, Amines, Diols, Sphingosine kinase, SK-1, Kinase, Sphingosine, Inflammatory cytokine

The patent is directed to methods for inhibiting the enzyme Sphingosine kinase 1 in patients using the companys proprietary compound SK1-I and related Sphingosine kinase 1 inhibitors.

Key Points: 
  • The patent is directed to methods for inhibiting the enzyme Sphingosine kinase 1 in patients using the companys proprietary compound SK1-I and related Sphingosine kinase 1 inhibitors.
  • Significantly, elevated levels of inflammatory cytokines, particularly IL-6, are reported to be associated with the development of respiratory failure in COVID-19 patients.
  • Elazar Rabbani, Ph.D., CEO of Enzo Biochem, Inc. commented: Enzos response to the COVID-19 pandemic has been multi-faceted.
  • The Company disclaims any obligations to update any forward-looking statement as a result of developments occurring after the date of this release.